Systemic adjuvant therapy for breast cancer.

Research output: Contribution to journalReview article

Abstract

The benefits of adjuvant systemic therapy in the treatment of early breast cancer are well established. However, many questions remain regarding the appropriate selection of patients and regimens, duration of treatment, timing or sequencing of treatment as well as the role of high-dose chemotherapy or new active drugs such as paclitaxel. Future answers will only come through continued participation in carefully designed clinical research.

Original languageEnglish (US)
Pages (from-to)48-50
Number of pages3
JournalThe Nebraska medical journal
Volume81
Issue number3
StatePublished - Mar 1996

Fingerprint

Breast Neoplasms
Therapeutics
Paclitaxel
Patient Selection
Drug Therapy
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Systemic adjuvant therapy for breast cancer. / Reed, E. C.

In: The Nebraska medical journal, Vol. 81, No. 3, 03.1996, p. 48-50.

Research output: Contribution to journalReview article

@article{eb8d8f3328744b1baa4352b820f45595,
title = "Systemic adjuvant therapy for breast cancer.",
abstract = "The benefits of adjuvant systemic therapy in the treatment of early breast cancer are well established. However, many questions remain regarding the appropriate selection of patients and regimens, duration of treatment, timing or sequencing of treatment as well as the role of high-dose chemotherapy or new active drugs such as paclitaxel. Future answers will only come through continued participation in carefully designed clinical research.",
author = "Reed, {E. C.}",
year = "1996",
month = "3",
language = "English (US)",
volume = "81",
pages = "48--50",
journal = "The Nebraska medical journal",
issn = "0091-6730",
publisher = "Nebraska State Medical Association",
number = "3",

}

TY - JOUR

T1 - Systemic adjuvant therapy for breast cancer.

AU - Reed, E. C.

PY - 1996/3

Y1 - 1996/3

N2 - The benefits of adjuvant systemic therapy in the treatment of early breast cancer are well established. However, many questions remain regarding the appropriate selection of patients and regimens, duration of treatment, timing or sequencing of treatment as well as the role of high-dose chemotherapy or new active drugs such as paclitaxel. Future answers will only come through continued participation in carefully designed clinical research.

AB - The benefits of adjuvant systemic therapy in the treatment of early breast cancer are well established. However, many questions remain regarding the appropriate selection of patients and regimens, duration of treatment, timing or sequencing of treatment as well as the role of high-dose chemotherapy or new active drugs such as paclitaxel. Future answers will only come through continued participation in carefully designed clinical research.

UR - http://www.scopus.com/inward/record.url?scp=0030090350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030090350&partnerID=8YFLogxK

M3 - Review article

C2 - 8907820

AN - SCOPUS:0030090350

VL - 81

SP - 48

EP - 50

JO - The Nebraska medical journal

JF - The Nebraska medical journal

SN - 0091-6730

IS - 3

ER -